Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2 + IL-12 gene-transfected KB cells
- Development stage
- Preclinical
- Lead developer
- Yokohama City University
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral
01
Overview
**IL-2 + IL-12 gene-transfected KB cells** is an experimental irradiated, gene-modified whole-tumor-cell vaccine evaluated preclinically for head and neck squamous cell carcinoma. It consists of human KB tumor cells separately engineered to express human interleukin-2 and murine interleukin-12, then administered together after irradiation. In a BALB/c nude-mouse KB tumor model, peritumoral administration of the combined cell preparations significantly inhibited established tumor growth, whereas either cytokine-transfected cell preparation alone was not substantially effective. ([jamanetwork.com](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/483998))
- Other names
- IL-2 + IL-12 gene-transfected KB cellsIL-2 and IL-12 gene-transfected KB cellsIL2 and IL-12 gene-transfected KB cellsIL 2 and IL-12 gene-transfected KB cellsKB/hIL-2 + KB/mIL-12 cellsKB/hIL-2 and KB/mIL-12 cells
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on IL-2 + IL-12 gene-transfected KB cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2 + IL-12 gene-transfected KB cells.